Why This Matters: A large Rutgers-led study has identified a possible link between widely used GLP-1 medications and ischemic optic neuropathy, a rare condition that can cause sudden, potentially permanent vision loss. The researchers emphasized that the absolute risk remained very low and that the findings do not prove the medications directly cause optic nerve damage.
What the study found
Researchers analyzed information from a large U.S. database of adults ages 18 to 65 with Type 2 diabetes who had recently started medication to manage their condition. The study examined glucagon-like peptide-1 receptor agonists, commonly known as GLP-1 medications.
The drugs included semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound. The study found that GLP-1 use was associated with a modest increase in the likelihood of ischemic optic neuropathy.
According to Chintan Dave of Rutgers, the estimated increase amounted to approximately three to four additional cases per 10,000 patients treated with GLP-1 medications over 18 months.
How ischemic optic neuropathy affects vision
Ischemic optic neuropathy occurs when blood flow to the optic nerve is reduced. The optic nerve carries visual information from the eye to the brain, so damage can cause significant vision problems.
The condition often affects part of the visual field in one eye rather than causing complete blindness. Reported symptoms may include sudden blurring, dimming or missing areas of vision.
More than 80% of ischemic optic neuropathy cases are estimated to involve the non-arteritic anterior form, in which blood supply to the front portion of the optic nerve becomes insufficient. Vision loss is often permanent, although Dave said approximately one-third of affected patients experience some recovery, usually during the first six months. Even then, some visual impairment typically remains.
Who appeared more likely to develop the condition?
Within the study population, cases were more common among men and adults in the older portion of the age range. The source report said most patients with ischemic optic neuropathy were men or adults ages 50 to 65.
These patterns describe characteristics observed among people who developed the condition in the study. They do not establish that every person in these groups faces the same level of risk.
Association is not proof of cause
The researchers cautioned that the study did not establish that GLP-1 medications directly cause optic nerve damage. Differences in patients’ underlying health conditions could help explain the observed association.
GLP-1 medications are used to help control blood sugar and manage weight, and the source report says they can reduce the risks of certain cardiovascular and kidney problems. Scientists are continuing to investigate potential side effects as use of the medications becomes more widespread.
What happens next
The findings support continued safety monitoring and further research to determine whether the medications themselves contribute to ischemic optic neuropathy. The report also emphasizes the importance of recognizing sudden changes in vision and seeking prompt medical evaluation, particularly for people who may already have a higher baseline risk.
Bottom Line
The Rutgers-led study found a small association between GLP-1 medication use and a rare form of optic nerve-related vision loss. The estimated risk was low, and the study did not prove that the drugs caused the condition. Further research is needed to clarify the connection.
Source
This report is based on information published by ScienceDaily Health & Medicine.
